Thermo Fisher Scientific

Thermo Fisher Scientific Announces Latest Round of Oncomine Clinical Research Grant Awardees

Retrieved on: 
Tuesday, February 20, 2024

Today, Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant , recognizing research from the Melanoma Institute Australia, the University of Turin in Italy and Atrium Health Wake Forest Baptist Medical Center.

Key Points: 
  • Today, Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant , recognizing research from the Melanoma Institute Australia, the University of Turin in Italy and Atrium Health Wake Forest Baptist Medical Center.
  • Since its introduction in 2020, the Oncomine Clinical Research Grant program has provided up to $200,000 in reagents and general funding for 22 unique research projects conducted by independent clinical research teams.
  • “The Oncomine Clinical Research Grant program provides us the opportunity to support emerging research projects and their goal of delivering on the promise of precision oncology through the democratization of NGS technology,” said Jose Luis Costa, Ph.D., global director, scientific affairs, clinical next-generation sequencing and oncology, Thermo Fisher Scientific.
  • In late 2023, Oncomine Clinical Research Grant recipients had the opportunity to attend a closed Oncomine Scientific Gala to share their research with the wider pharmaceutical community and showcase the results of their studies and the impact NGS testing can have on oncology research and patient care.

Sugar Land, Texas, Lands $4 Million Expansion for New Frazer Headquarters

Retrieved on: 
Thursday, March 7, 2024

SUGAR LAND, Texas, March 7, 2024 /PRNewswire-PRWeb/ -- In an agreement facilitated by Sugar Land Economic Development and Tourism (SLOEDT), Frazer, the nation's leading provider of emergency vehicles, will invest $4 million to relocate its headquarters from Houston to Sugar Land, Texas. The company will occupy a 150,000-square-foot space at 1410 Gillingham Lane and create 286 new jobs with an average annual salary of $71,000.

Key Points: 
  • SUGAR LAND, Texas, March 7, 2024 /PRNewswire-PRWeb/ -- In an agreement facilitated by Sugar Land Economic Development and Tourism (SLOEDT) , Frazer , the nation's leading provider of emergency vehicles, will invest $4 million to relocate its headquarters from Houston to Sugar Land, Texas.
  • "Being just minutes outside of Houston, Sugar Land has always been on our radar," said Laura A. Griffin, CEO of Frazer.
  • This news follows Accredo Packaging's fourth expansion in Sugar Land, representing a $10 million investment, and SouthWest Water Company's expansion, which created 100 new jobs.
  • Located 20 minutes southwest of downtown Houston, Sugar Land is home to 12.4 million square feet of industrial/flex space, and 9.1 million square feet of office real estate.

Nicklaus Children's Hospital is the first Pediatric Hospital in South Florida to Adopt Innovative Pharmacogenomics Testing Technology to Personalize Patient Treatment Plans

Retrieved on: 
Thursday, February 29, 2024

MIAMI, Feb. 29, 2024 /PRNewswire/ -- Nicklaus Children's Hospital is the first children's hospital in South Florida to offer in-house pharmacogenomics testing with the Applied Biosystems™ PharmacoScan Solution* and GeneTitan MC Fast Scan Instrument*.

Key Points: 
  • MIAMI, Feb. 29, 2024 /PRNewswire/ -- Nicklaus Children's Hospital is the first children's hospital in South Florida to offer in-house pharmacogenomics testing with the Applied Biosystems™ PharmacoScan Solution* and GeneTitan MC Fast Scan Instrument*.
  • Pharmacogenomics testing uses a person's genetics to determine the most effective, safest medications and dosage.
  • Care teams across the hospital automatically receive alerts to help guide treatment decisions if pharmacogenomics test information is available for a patient in their care.
  • "We look forward to continuing to collaborate with Nicklaus Children's Hospital to advance their precision medicine program and improve patient outcomes."

VALISURE ANNOUNCES NEW VENTURE PARTNERS AND EXPANSION OF LEADERSHIP TEAM

Retrieved on: 
Wednesday, February 28, 2024

NEW HAVEN, Conn., Feb. 28, 2024 /PRNewswire/ -- Valisure, a healthcare industry pioneer for independent quality assurance in pharmaceutical drugs, has recently received substantial investments from leading healthcare venture capital firms to accelerate Valisure's rapid growth and impact. Concurrently, the company is pleased to announce key leadership developments, including appointing a highly experienced healthcare leader as CEO and additional expansion of its executive team.

Key Points: 
  • Concurrently, the company is pleased to announce key leadership developments, including appointing a highly experienced healthcare leader as CEO and additional expansion of its executive team.
  • Valisure has gained global recognition for its commitment to ensuring the safety and quality of medications through its highly impactful, independent testing.
  • "I look forward to collaborating with the talented team and enabling Valisure to expand its work with the industry to strategically address these issues."
  • Likewise, Wolfgang Hinz, Ph.D., has assumed a pivotal leadership position as the Chief Scientific Officer of Valisure.

Real World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 16, 2024

Real World Evidence Solutions Market Dynamics:

Key Points: 
  • Real World Evidence Solutions Market Dynamics:
    Key Market Players of Real World Evidence Solutions Industry:
    Prominent players in the Real-World Evidence Solution market include Iqvia Holdings Inc. (US), Merative(US), Optum Inc. (US), Icon Plc.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the Real-World Evidence Solution market.
  • Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Real-World Evidence Solution market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global real-world evidence solution Market.

Real World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 16, 2024

Real World Evidence Solutions Market Dynamics:

Key Points: 
  • Real World Evidence Solutions Market Dynamics:
    Key Market Players of Real World Evidence Solutions Industry:
    Prominent players in the Real-World Evidence Solution market include Iqvia Holdings Inc. (US), Merative(US), Optum Inc. (US), Icon Plc.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the Real-World Evidence Solution market.
  • Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Real-World Evidence Solution market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global real-world evidence solution Market.

Thermo Fisher Scientific Recognized by Customers for Contract Manufacturing Leadership

Retrieved on: 
Friday, February 16, 2024

For the 11th consecutive year, Thermo Fisher Scientific’s pharma and biopharma customers recognized its contract manufacturing excellence through the annual CDMO Leadership awards sponsored by Outsourced Pharma and Life Science Connect.

Key Points: 
  • For the 11th consecutive year, Thermo Fisher Scientific’s pharma and biopharma customers recognized its contract manufacturing excellence through the annual CDMO Leadership awards sponsored by Outsourced Pharma and Life Science Connect.
  • In total, customers evaluated 98 companies across 23 performance metrics for these honors, which distinguish the top contract manufacturing organizations by surveying leading global pharma and biotech companies.
  • That research, based on the Contract Manufacturing Quality Benchmarking conducted by Industry Standard Research (ISR), involved customers of all sizes that worked with the contract manufacturers during the prior 18 months.
  • Those best at serving their customers (and thus patients) are recognized as the 2024 CDMO Leadership Award winners.

ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

Retrieved on: 
Thursday, February 15, 2024

LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications. Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company’s Senior Leadership Team.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications.
  • Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company’s Senior Leadership Team.
  • Ms. Lee began her investor relations career at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014.
  • “I am honored to join ACELYRIN to lead the investor relations and corporate communications functions as we progress on our corporate journey in support of patients,” said Ms. Lee.

Bioburden Testing Market worth $2.59 billion by 2031 Owing To Increasing Demand for Quality Assurance and Safety Measures - Exclusive Report by Coherent Market Insights

Retrieved on: 
Thursday, February 15, 2024

The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.

Key Points: 
  • The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.
  • Their strong market presence and diverse product portfolio contribute to the overall growth of the bioburden testing market.
  • In summary, the bioburden testing market presents significant opportunities, with the consumables segment and aerobic count testing expected to dominate.
  • These market takeaways highlight the key factors influencing the bioburden testing market's growth and offer insights into its future direction.

Bioburden Testing Market worth $2.59 billion by 2031 Owing To Increasing Demand for Quality Assurance and Safety Measures - Exclusive Report by Coherent Market Insights

Retrieved on: 
Thursday, February 15, 2024

The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.

Key Points: 
  • The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.
  • Their strong market presence and diverse product portfolio contribute to the overall growth of the bioburden testing market.
  • In summary, the bioburden testing market presents significant opportunities, with the consumables segment and aerobic count testing expected to dominate.
  • These market takeaways highlight the key factors influencing the bioburden testing market's growth and offer insights into its future direction.